Pier Luigi Temporelli
Overview
Explore the profile of Pier Luigi Temporelli including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
134
Citations
1391
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Temporelli P
Eur Heart J Suppl
. 2024 Jun;
26(Suppl 1):i127-i130.
PMID: 38867875
Heart failure with preserved ejection fraction (HFpEF) currently represents the majority of all heart failure cases in the community. Glucagon-like peptide-1 agonists represent a class of medications used to treat...
12.
Luca F, Oliva F, Abrignani M, Di Fusco S, Gori M, Giubilato S, et al.
J Clin Med
. 2024 Apr;
13(5).
PMID: 38592244
Heart failure with preserved ejection fraction (HFpEF) is characterized by a notable heterogeneity in both phenotypic and pathophysiological features, with a growing incidence due to the increase in median age...
13.
Di Fusco S, Abrignani M, Amico A, Luca F, Mureddu G, Ceravolo R, et al.
G Ital Cardiol (Rome)
. 2024 Mar;
25(4):239-251.
PMID: 38526360
Atherosclerosis is a systemic disease that can involve different arterial districts. Traditionally, the focus of cardiologists has been on the diagnosis and treatment of atherosclerotic coronary artery disease (CAD). However,...
14.
Tikhonoff V, Casiglia E, Virdis A, Grassi G, Angeli F, Arca M, et al.
J Am Heart Assoc
. 2024 Jan;
13(3):e030319.
PMID: 38293920
Background: Despite longstanding epidemiologic data on the association between increased serum triglycerides and cardiovascular events, the exact level at which risk begins to rise is unclear. The Working Group on...
15.
Abrignani M, Gronda E, Marini M, Gori M, Iacoviello M, Temporelli P, et al.
Cardiovasc Drugs Ther
. 2024 Jan;
PMID: 38289453
Hyperkalaemia is one of the most common electrolyte disorders in patients with cardiovascular disease (CVD). The true burden of hyperkalaemia in the real-world setting can be difficult to assess, but...
16.
Abrignani M, Maloberti A, Di Fusco S, Luca F, Cesaro A, Acerbo V, et al.
G Ital Cardiol (Rome)
. 2024 Jan;
25(2):76-87.
PMID: 38270363
Lipoprotein(a) [Lp(a)] is a well-established cardiovascular risk factor, whose relationship with atherosclerotic disease has been confirmed by epidemiological, genome-wide association, Mendelian randomization, and meta-analysis studies. This association is determined by...
17.
Zuin M, Rigatelli G, Cavedon S, Temporelli P, Bilato C
Intern Emerg Med
. 2023 Dec;
19(2):423-428.
PMID: 38112986
We sought to analyse the incidence of sudden cardiac deaths (SCDs) amongst subjects aged less than 39 years in Italy and its time trend between 2013 and 2019. Data regarding...
18.
De Luca L, Temporelli P, Gulizia M, Gonzini L, Ammaturo T, Tedesco L, et al.
Nutr Metab Cardiovasc Dis
. 2023 Oct;
33(12):2398-2405.
PMID: 37788956
Background And Aim: Elevated triglyceride (TG) levels seem to identify subjects at increased cardiovascular risk, independent of LDL-C levels. We sought to evaluate the predictive role of hypertriglyceridemia, defined as...
19.
Giubilato S, Luca F, Abrignani M, Gatto L, Rao C, Ingianni N, et al.
J Clin Med
. 2023 Sep;
12(18).
PMID: 37762932
Chronic coronary syndrome (CCS), which encompasses a broad spectrum of clinical presentations of coronary artery disease (CAD), is the leading cause of morbidity and mortality worldwide. Recent guidelines for the...
20.
Luca F, Oliva F, Abrignani M, Di Fusco S, Parrini I, Canale M, et al.
J Clin Med
. 2023 Sep;
12(18).
PMID: 37762897
It is well established that direct oral anticoagulants (DOACs) are the cornerstone of anticoagulant strategy in atrial fibrillation (AF) and venous thromboembolism (VTE) and should be preferred over vitamin K...